Compositions and methods for promoting hemostasis and other physiological activities

Patent metadata

Field	Value
Publication number	US-9327010-B2
Application number	US-41174506-A
Country	US
Kind code	B2
Filing date	Apr 25, 2006
Priority date	Apr 25, 2005
Publication date	May 3, 2016
Grant date	May 3, 2016

Abstract

Compositions that include nanoscale structured materials or precursors thereof (e.g., self-assembling peptides) are described. The compositions can include other substances (e.g., a vasoconstrictor). Also described are methods for using the compositions to promote hemostasis, to protect the skin or wounds from contamination, to decontaminate a site upon removal of previously applied compositions that provided a protective coating, and to inhibit the movement of bodily substances other than blood. The compositions are also useful in isolating tissue, removing tissue, preserving tissue (for, e.g., subsequent transplantation or reattachment), and as bulking, stabilizing or hydrating agents. Medical devices that include the compositions (e.g., a stent or catheter), bandages or other wound dressings, sutures, and kits that include the compositions are also described.

First claim

What is claimed is:

1. A formulation for making an in vivo barrier structure, comprising:
self-assembling peptides,
wherein the self-assembling peptides consist of a sequence of from 8 to 16 amino acid residues conforming to one or more of Formulas I-IV:
((Xaa neu -Xaa + ) x (Xaa neu -Xaa − ) y ) n   (I)

((Xaa neu -Xaa − ) x (Xaa neu -Xaa + ) y ) n   (II)

((Xaa + -Xaa neu ) x (Xaa − Xaa neu ) y ) n   (III)

((Xaa − -Xaa neu ) x (Xaa + Xaa neu ) y ) n   (IV)

wherein Xaa neu represents alanine or leucine; Xaa + represents arginine or lysine; Xaa − represents aspartic acid or glutamic acid; x and y are integers having a value of 1 or 2, or 4, independently; and n is an integer having a value of 1-4,
wherein the self-assembling peptides are in an effective concentration to self-assemble upon contact with physiological fluids at an exposed surgical incision site or an exposed wound site of an animal to form a macroscopic structure that inhibits or prevents passage of bodily fluid through the structure,
wherein the barrier structure is formed by application of a powder or an aqueous solution of the self-assembling peptides to the exposed surgical incision site or exposed wound site,
wherein the solution has a total concentration of less than 5 mM Li+, Na+, K+, and Cs+ ions and a concentration of self-assembling peptides between 1.0% weight to volume and 4.0% weight to volume inclusive.

2. The formulation for making the barrier structure of claim 1 , wherein the aqueous solution of the peptides further comprises a pharmaceutically acceptable carrier and/or a non-fibrous agent.

3. The formulation for making the barrier structure of claim 1 , further comprising a therapeutic agent, prophylactic agent, diagnostic agent, a pharmaceutically acceptable diluent, filler, or oil.

4. The formulation of claim 3 , further comprising anti-inflammatories, vasoconstrictors, anti-infectives, anesthetics, growth factors, cells, organic compounds, biomolecules, coloring agents, vitamins, or metals.

5. The formulation of claim 1 , wherein the self-assembling peptides are in an aqueous solution at a concentration of between 1.0% weight to volume to 3.0% weight to volume, inclusive.

6. The formulation of claim 5 , wherein the self-assembling peptides are in an aqueous solution at a concentration of between 2.0% weight to volume to 3.0% weight to volume.

7. The formulation of claim 1 ,
wherein the self-assembling peptides comprise the amino acid sequence RADARADARADARADA (SEQ ID NO: 1).

Assignees

• Ellis-Behnke Rutledge
• Zhang Shuguang
• Schneider Gerald
• So Kwok-Fai
• Tay David
• Liang Yu-Xiang
• Massachusetts Inst Technology
• Versitech Ltd

Inventors

• Ellis-Behnke Rutledge
• Zhang Shuguang
• Schneider Gerald
• So Kwok-Fai
• Tay David
• Liang Yu-Xiang

Classifications

• A61P41/00

  Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution · CPC title

• A61P9/14

  Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers · CPC title

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title